Literature DB >> 20482679

Stem cell marker upregulation in normal cutaneous vessels following pulsed-dye laser exposure and its abrogation by concurrent rapamycin administration: implications for treatment of port-wine stain birthmarks.

Robert Loewe1, Darryl A Oble, Teresa Valero, Lawrence Zukerberg, Martin C Mihm, J Stuart Nelson.   

Abstract

Port-wine stains (PWS) represent a group of vascular malformations that are usually accompanied by psychological distress for affected patients, often reflected in high treatment demand. Although the pulsed-dye laser (PDL) was established as standard therapy for PWS more than a decade ago, therapeutic outcome may be unsatisfactory. One of the main drawbacks to successful PDL therapy is PWS revascularization shortly after laser exposure. Therefore, inhibition of revascularization should improve therapeutic outcome of PDL therapy. In this study, we first evaluated the effects of various light energies on normal cutaneous vessels over a period of 14 days, particularly the proliferation and stem cell marker expression of dermal endothelial cells, which were found to be highest 8 days following laser exposure. We found that PDL exposure induced dose-dependent damage of dermal vessels up to energy densities of 6 J/cm(2), above which no increase in PDL-induced effects were observed with the energies employed in this study. In dermal endothelial cells of PDL-exposed skin, we found strong expression of the proliferation marker Ki-67 as well as the stem cell marker nestin but not other stem cell markers such as CD133 and CD166. The influence of rapamycin (RPM), used as an adjuvant to PDL exposure, was also investigated. RPM administration reduced Ki-67 and nestin expression in dermal endothelial cells and increased PDL-induced destruction of dermal vessels, indicating that the use of RPM after PDL exposure may be an interesting new approach for prolonging and improving PWS laser therapeutic outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20482679      PMCID: PMC3160814          DOI: 10.1111/j.1600-0560.2010.01520.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  28 in total

1.  Sirolimus approved with renal transplant indication.

Authors:  J L Miller
Journal:  Am J Health Syst Pharm       Date:  1999-11-01       Impact factor: 2.637

2.  Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2.

Authors:  Weimin Li; Marco Petrimpol; Klaus D Molle; Michael N Hall; Edouard J Battegay; Rok Humar
Journal:  Circ Res       Date:  2006-11-16       Impact factor: 17.367

3.  The effect of varying pulse duration, wavelength, spot size, and fluence on the response of previously treated capillary vascular malformations to pulsed-dye laser treatment.

Authors:  Vivek Sivarajan; William M Maclaren; Iain R Mackay
Journal:  Ann Plast Surg       Date:  2006-07       Impact factor: 1.539

Review 4.  TOR signaling in growth and metabolism.

Authors:  Stephan Wullschleger; Robbie Loewith; Michael N Hall
Journal:  Cell       Date:  2006-02-10       Impact factor: 41.582

Review 5.  Treatment of pulsed dye laser-resistant port wine stain birthmarks.

Authors:  Zaid F Jasim; Julian M Handley
Journal:  J Am Acad Dermatol       Date:  2007-07-19       Impact factor: 11.527

6.  Can the wound healing response of human skin be modulated after laser treatment and the effects of exposure extended? Implications on the combined use of the pulsed dye laser and a topical angiogenesis inhibitor for treatment of port wine stain birthmarks.

Authors:  Thuy L Phung; Darryl A Oble; Wangcun Jia; Laura E Benjamin; Martin C Mihm; J Stuart Nelson
Journal:  Lasers Surg Med       Date:  2008-01       Impact factor: 4.025

7.  Identification of neovasculature using nestin in colorectal cancer.

Authors:  Nobuhisa Teranishi; Zenya Naito; Toshiyuki Ishiwata; Noritake Tanaka; Kiyonori Furukawa; Tomoko Seya; Seiichi Shinji; Takashi Tajiri
Journal:  Int J Oncol       Date:  2007-03       Impact factor: 5.650

Review 8.  The pluripotency of hair follicle stem cells.

Authors:  Robert M Hoffman
Journal:  Cell Cycle       Date:  2006-02-09       Impact factor: 4.534

9.  Nestin-linked green fluorescent protein transgenic nude mouse for imaging human tumor angiogenesis.

Authors:  Yasuyuki Amoh; Meng Yang; Lingna Li; Jose Reynoso; Michael Bouvet; Abdool R Moossa; Kensei Katsuoka; Robert M Hoffman
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

10.  Effects of lower fluence pulsed dye laser irradiation on production of collagen and the mRNA expression of collagen relative gene in cultured fibroblasts in vitro.

Authors:  Hai-yan Yu; Da-fang Chen; Qi Wang; Hao Cheng
Journal:  Chin Med J (Engl)       Date:  2006-09-20       Impact factor: 2.628

View more
  10 in total

1.  Observations on enhanced port wine stain blanching induced by combined pulsed dye laser and rapamycin administration.

Authors:  J Stuart Nelson; Wangcun Jia; Thuy L Phung; Martin C Mihm
Journal:  Lasers Surg Med       Date:  2011-11-29       Impact factor: 4.025

Review 2.  [New developments in laser therapy].

Authors:  P Babilas; M Landthaler
Journal:  Hautarzt       Date:  2012-04       Impact factor: 0.751

Review 3.  An overview of clinical and experimental treatment modalities for port wine stains.

Authors:  Jennifer K Chen; Pedram Ghasri; Guillermo Aguilar; Anne Margreet van Drooge; Albert Wolkerstorfer; Kristen M Kelly; Michal Heger
Journal:  J Am Acad Dermatol       Date:  2012-02-03       Impact factor: 11.527

Review 4.  Laser and IPL treatment of port-wine stains: therapy options, limitations, and practical aspects.

Authors:  Annette Klein; Wolfgang Bäumler; Michael Landthaler; Philipp Babilas
Journal:  Lasers Med Sci       Date:  2011-03-10       Impact factor: 3.161

Review 5.  Noninvasive clinical assessment of port-wine stain birthmarks using current and future optical imaging technology: a review.

Authors:  S A Sharif; E Taydas; A Mazhar; R Rahimian; K M Kelly; B Choi; A J Durkin
Journal:  Br J Dermatol       Date:  2012-10-05       Impact factor: 9.302

6.  Enhanced port-wine stain lightening achieved with combined treatment of selective photothermolysis and imiquimod.

Authors:  Anne Marie Tremaine; Jennifer Armstrong; Yu-Chih Huang; Leila Elkeeb; Arisa Ortiz; Ronald Harris; Bernard Choi; Kristen M Kelly
Journal:  J Am Acad Dermatol       Date:  2012-01-14       Impact factor: 11.527

7.  Topical rapamycin systematically suppresses the early stages of pulsed dye laser-induced angiogenesis pathways.

Authors:  Lin Gao; Sydney Phan; Dawnica Mercado Nadora; Margarita Chernova; Victor Sun; Salena Marie Oaxaca Preciado; Brittany Ballew; Zhenyu Jia; Wangcun Jia; Gang Wang; Martin C Mihm; J Stuart Nelson; Wenbin Tan
Journal:  Lasers Surg Med       Date:  2014-09-30       Impact factor: 4.025

8.  Topical rapamycin suppresses the angiogenesis pathways induced by pulsed dye laser: molecular mechanisms of inhibition of regeneration and revascularization of photocoagulated cutaneous blood vessels.

Authors:  Wenbin Tan; Wangcun Jia; Victor Sun; Martin C Mihm; J Stuart Nelson
Journal:  Lasers Surg Med       Date:  2012-12-04       Impact factor: 4.025

9.  Outcome with topical sirolimus for port wine stain malformations after unsatisfactory results with pulse dye laser treatment alone.

Authors:  Hebah Mohammadsalam Musalem; Aljoharah Abdulaziz Alshaikh; Lin M Tuleimat; Saad Alajlan
Journal:  Ann Saudi Med       Date:  2018 Sep-Oct       Impact factor: 1.526

10.  Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.

Authors:  Sandra D Castillo; Elena Tzouanacou; May Zaw-Thin; Inma M Berenjeno; Victoria E R Parker; Iñigo Chivite; Maria Milà-Guasch; Wayne Pearce; Isabelle Solomon; Ana Angulo-Urarte; Ana M Figueiredo; Robert E Dewhurst; Rachel G Knox; Graeme R Clark; Cheryl L Scudamore; Adam Badar; Tammy L Kalber; Julie Foster; Daniel J Stuckey; Anna L David; Wayne A Phillips; Mark F Lythgoe; Valerie Wilson; Robert K Semple; Neil J Sebire; Veronica A Kinsler; Mariona Graupera; Bart Vanhaesebroeck
Journal:  Sci Transl Med       Date:  2016-03-30       Impact factor: 17.956

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.